Preferences of Patients and Health Professionals for Route and Frequency of Administration of Biologic Agents in the Treatment of Rheumatoid Arthritis

Overview

Journal Patient Prefer Adherence

Date 2014 Jan 29

PMID 24470758

Citations 39

Authors

Tuan Khai Huynh

Ann Ostergaard

Charlotte Egsmose

Ole Rintek Madsen

Affiliations

Soon will be listed here.

Abstract

Objectives: To examine the preferences of rheumatoid arthritis (RA) patients and health professionals (HPs) for the route and frequency of administration of biologic drugs.

Methods: One hundred and seven RA patients treated with biological agents for intravenous or subcutaneous use, 35 biologic-naïve RA patients treated with a disease-modifying antirheumatic drug and 30 rheumatology HPs (physicians and nurses) were recruited from two outpatient clinics in Copenhagen, Denmark. All subjects filled out a questionnaire interrogating their choice of preferred route and frequency of administration of a biologic corresponding to current available options, given that effects, adverse effects, and financial costs were identical for the different choices. The subjects were also asked to justify their preferences. The chi-square goodness-of-fit test was used to examine the distributions over different preferences. Proportions were compared using Fisher's exact test.

Results: Forty-one patients were currently treated with subcutaneous self-injections at home (SCH) and 66 intravenously at the clinic (IVC). IVC was preferred by 85% of patients currently treated with IVC (P<0.0001). SCH was preferred by 71% of patients currently treated with SCH (P<0.001), by 77% of the biologic-naïve patients (P<0.01), and by 87% of HPs (P<0.0001). The proportion of patients favoring SCH was significantly higher for patients currently receiving SCH and for biologic-naïve RA patients than for those currently on IVC (P<0.0001). SCH once a month and IVC every 8 weeks were the most appealing treatment frequencies (P<0.01). The most frequent reason among patients for choosing IVC or SCH was a wish for safety, and a wish to minimize the time of transportation and treatment, respectively.

Conclusion: The majority of RA patients treated with biologics preferred their current route of administration. Most patients, those inexperienced with biologics, and HPs favored SCH. Low treatment frequencies were generally preferred.

Citing Articles

Switching from Dose-Intensified intravenous to SubCutaneoUS infliximab in Inflammatory Bowel Disease (DISCUS-IBD): protocol for a multicentre randomised controlled trial.

Little R, McKenzie J, Srinivasan A, Hilley P, Gilmore R, Chee D BMJ Open. 2024; 14(7):e081787.

PMID: 39032928 PMC: 11261670. DOI: 10.1136/bmjopen-2023-081787.

Prevention of bleomycin-induced pulmonary fibrosis by vaccination with the Tocilizumab mimotope.

Guo J, Yang L, Song H, Bai L Hum Vaccin Immunother. 2024; 20(1):2319965.

PMID: 38408907 PMC: 10900270. DOI: 10.1080/21645515.2024.2319965.

Expenditure of biological drugs for rheumatoid arthritis treatment in the Brazilian public health system.

Mega T, da Silva R Rev Saude Publica. 2023; 57:41.

PMID: 37556663 PMC: 10355319. DOI: 10.11606/s1518-8787.2023057004280.

Customer-centric product presentations for monoclonal antibodies.

Bittner B AAPS Open. 2023; 9(1):3.

PMID: 36713112 PMC: 9869842. DOI: 10.1186/s41120-022-00069-y.

Efficacy of subcutaneous vs intravenous infliximab in rheumatoid arthritis: a post-hoc analysis of a randomized phase III trial.

Constantin A, Caporali R, Edwards C, Fonseca J, Iannone F, Keystone E Rheumatology (Oxford). 2022; 62(8):2838-2844.

PMID: 36534825 PMC: 10393429. DOI: 10.1093/rheumatology/keac689.

References

Singh J, Furst D, Bharat A, Curtis J, Kavanaugh A, Kremer J . 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012; 64(5):625-39. PMC: 4081542. DOI: 10.1002/acr.21641. View

Martin R, Head A, Rene J, Swartz T, Fiechtner J, McIntosh B . Patient decision-making related to antirheumatic drugs in rheumatoid arthritis: the importance of patient trust of physician. J Rheumatol. 2008; 35(4):618-24. View

Fraenkel L, McGraw S . What are the essential elements to enable patient participation in medical decision making?. J Gen Intern Med. 2007; 22(5):614-9. PMC: 1855272. DOI: 10.1007/s11606-007-0149-9. View

Pullar T, WRIGHT V, Feely M . What do patients and rheumatologists regard as an 'acceptable' risk in the treatment of rheumatic disease?. Br J Rheumatol. 1990; 29(3):215-8. DOI: 10.1093/rheumatology/29.3.215. View

Williams E, Edwards C . Patient preferences in choosing anti-TNF therapies-R1. Rheumatology (Oxford). 2006; 45(12):1575-6. DOI: 10.1093/rheumatology/kel369. View

Aaltonen K, Virkki L, Malmivaara A, Konttinen Y, Nordstrom D, Blom M . Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis. PLoS One. 2012; 7(1):e30275. PMC: 3260264. DOI: 10.1371/journal.pone.0030275. View

Goekoop-Ruiterman Y, de Vries-Bouwstra J, Allaart C, Kerstens P, Grillet B, de Jager M . Patient preferences for treatment: report from a randomised comparison of treatment strategies in early rheumatoid arthritis (BeSt trial). Ann Rheum Dis. 2007; 66(9):1227-32. PMC: 1955131. DOI: 10.1136/ard.2006.068296. View

Yazici Y, McMorris B, Darkow T, Rosenblatt L . Patient and physician perception of the infusion process of the biologic agents abatacept, infliximab, and rituximab for the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2010; 27(6):907-13. View

Gabriel S, Michaud K . Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Res Ther. 2009; 11(3):229. PMC: 2714099. DOI: 10.1186/ar2669. View

10.

Curtis J, Chen L, Harrold L, Narongroeknawin P, Reed G, Solomon D . Physician preference motivates the use of anti-tumor necrosis factor therapy independent of clinical disease activity. Arthritis Care Res (Hoboken). 2010; 62(1):101-7. PMC: 2913388. DOI: 10.1002/acr.20020. View

11.

Kirwan J, Hewlett S, Heiberg T, Hughes R, Carr M, Hehir M . Incorporating the patient perspective into outcome assessment in rheumatoid arthritis--progress at OMERACT 7. J Rheumatol. 2005; 32(11):2250-6. View

12.

Ho M, Lavery B, Pullar T . The risk of treatment. A study of rheumatoid arthritis patients' attitudes. Br J Rheumatol. 1998; 37(4):459-60. DOI: 10.1093/rheumatology/37.4.459. View

13.

Fraenkel L, Fried T . Individualized medical decision making: necessary, achievable, but not yet attainable. Arch Intern Med. 2010; 170(6):566-9. PMC: 2845319. DOI: 10.1001/archinternmed.2010.8. View

14.

Keystone E, Smolen J, van Riel P . Developing an effective treatment algorithm for rheumatoid arthritis. Rheumatology (Oxford). 2012; 51 Suppl 5:v48-54. DOI: 10.1093/rheumatology/kes122. View

15.

Choy E, Kavanaugh A, Jones S . The problem of choice: current biologic agents and future prospects in RA. Nat Rev Rheumatol. 2013; 9(3):154-63. DOI: 10.1038/nrrheum.2013.8. View

16.

Scarpato S, Antivalle M, Favalli E, Nacci F, Frigelli S, Bartoli F . Patient preferences in the choice of anti-TNF therapies in rheumatoid arthritis. Results from a questionnaire survey (RIVIERA study). Rheumatology (Oxford). 2009; 49(2):289-94. DOI: 10.1093/rheumatology/kep354. View

17.

Marshall N, Wilson G, Lapworth K, Kay L . Patients' perceptions of treatment with anti-TNF therapy for rheumatoid arthritis: a qualitative study. Rheumatology (Oxford). 2004; 43(8):1034-8. DOI: 10.1093/rheumatology/keh237. View

18.

van Hulst L, Kievit W, van Bommel R, Van Riel P, Fraenkel L . Rheumatoid arthritis patients and rheumatologists approach the decision to escalate care differently: results of a maximum difference scaling experiment. Arthritis Care Res (Hoboken). 2011; 63(10):1407-14. PMC: 3698485. DOI: 10.1002/acr.20551. View

19.

Kennedy T, McCabe C, Struthers G, Sinclair H, Chakravaty K, Bax D . BSR guidelines on standards of care for persons with rheumatoid arthritis. Rheumatology (Oxford). 2005; 44(4):553-6. DOI: 10.1093/rheumatology/keh554. View

20.

Cunha-Miranda L, Costa L, Ribeiro J . NEAR study: Needs and Expectations in Rheumatoid ARthritis - do we know our patients needs?. Acta Reumatol Port. 2010; 35(3):314-23. View